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BACKGROUND AND PURPOSE
Idiopathic pulmonary fibrosis (IPF) is a progressive fibro-proliferative disorder refractory to current therapy commonly
complicated by the development of pulmonary hypertension (PH); the associated morbidity and mortality are substantial.
Natriuretic peptides possess vasodilator and anti-fibrotic actions, and pharmacological augmentation of their bioactivity
ameliorates renal and myocardial fibrosis. Here, we investigated whether natriuretic peptides possess an intrinsic
cytoprotective function preventing the development of pulmonary fibrosis and associated PH, and whether therapeutics
targeting natriuretic peptide signalling demonstrate efficacy in this life-threatening disorder.
EXPERIMENTAL APPROACH
Pulmonary haemodynamics, right ventricular function and markers of lung fibrosis were determined in wild-type (WT) and
natriuretic peptide receptor (NPR)-A knockout (KO) mice exposed to bleomycin (1 mg·kg−1). Human myofibroblast
differentiation was studied in vitro.
KEY RESULTS
Exacerbated cardiac, vascular and fibrotic pathology was observed in NPR-A KO animals, compared with WT mice, exposed to
bleomycin. Treatment with a drug combination that raised circulating natriuretic peptide levels (ecadotril) and potentiated
natriuretic peptide-dependent signalling (sildenafil) reduced indices of disease progression, whether administered
prophylactically or to animals with established lung disease. This positive pharmacodynamic effect was diminished in NPR-A
KO mice. Atrial natriuretic peptide and sildenafil synergistically reduced TGFβ-induced human myofibroblast differentiation, a
key driver of remodelling in IPF patients.
CONCLUSIONS AND IMPLICATIONS
These data highlight an endogenous host-defence capacity of natriuretic peptides in lung fibrosis and PH. A combination of
ecadotril and sildenafil reversed the pulmonary haemodynamic aberrations and remodelling that characterize the disease,
advocating therapeutic manipulation of natriuretic peptide bioactivity in patients with IPF.
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αSMA, α smooth muscle actin; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; ILD, interstitial lung
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neutral endopeptidase inhibitor; NPR, natriuretic peptide receptor; PDE5i, phosphodiesterase 5 inhibitor; PH,
pulmonary hypertension; RVH, right ventricular hypertrophy; RVSP, right ventricular systolic pressure; WT, wild-type
Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal
lung disorder resulting from unrelenting matrix deposition
and diminution of lung function (Bjoraker et al., 1998;
Eickelberg and Selman, 2010). IPF is the most common inter-
stitial lung disease (ILD) and carries the worst prognosis, with
median survival ranging from 2 to 3 years (Martinez et al.,
2005; Eickelberg and Selman, 2010; Ley et al., 2011). Pulmo-
nary hypertension (PH), characterized by increased pulmo-
nary vascular resistance, remodelling of the small pulmonary
arteries and right ventricular hypertrophy (RVH), is a
common complication in IPF (affecting 30–40% of patients),
and individuals with a dual diagnosis exhibit markedly
reduced survival (Lettieri et al., 2006; Mejia et al., 2009). PH is
also frequently associated with other ILDs, including sys-
temic sclerosis-driven pulmonary fibrosis, where it also
results in increased mortality (Behr and Ryu, 2008; Condliffe
et al., 2009). IPF is refractory to virtually all current therapeu-
tic options and the recently licensed anti-fibrotic, anti-
inflammatory drug pirfenidone achieves only a small
treatment benefit at high financial cost (Noble et al., 2011).
Therefore, identification of novel mechanisms underpinning
pathogenesis and potential therapeutic targets that possess
the ability to combat both the altered pulmonary haemody-
namics and fibro-proliferative lung phenotype is of high
priority.
Natriuretic peptides are a family of vasodilator hormones
that play a pivotal role in the regulation of blood volume and
blood pressure (Lee and Burnett Jr, 2007; Potter et al., 2009).
Atrial natriuretic peptide (ANP) and brain natriuretic peptide
(BNP) are released predominantly from the heart, while a
third member of this family, C-type natriuretic peptide, is
released principally from endothelial cells. These peptides act
via guanylyl cyclase-linked receptors to promote cGMP pro-
duction, salt and water excretion, and peripheral vasodilata-
tion. Natriuretic peptides and their cognate receptors have
also been localized to many areas of the lung, including
peripheral lung tissues, airway epithelium and pulmonary
vasculature (Bianchi et al., 1985; Sakamoto et al., 1986;
Gutkowska et al., 1987; Toshimori et al., 1988; receptor
nomenclature follows Alexander et al., 2013), and are
thought to play a key role in lung physiology, regulating
several processes, including vasodilation, bronchorelaxation,
pulmonary permeability and surfactant production (Hulks
et al., 1990; Perreault and Gutkowska, 1995).
We have recently reported that augmentation of endog-
enous natriuretic peptide bioactivity, using ecadotril, an
inhibitor of neutral endopeptidase [NEPi; an enzyme that
metabolizes and inactivates natriuretic peptides (Kenny and
Stephenson, 1988; Soleilhac et al., 1992)] in tandem with
sildenafil, an inhibitor of phosphodiesterase 5 [PDE5i, hydro-
lyses and inactivates cGMP (Bender and Beavo, 2006)] and
first-line treatment of PH, prevents and reverses pathogenesis
in a hypoxic model of PH (Baliga et al., 2008). The natriuretic
peptide family is also known to exert anti-proliferative and
anti-fibrotic bioactivity in the heart and kidney (Tamura et al.,
2000; Knowles et al., 2001). Here, we have used a well-
characterized model of lung fibrosis induced by bleomycin, to
establish a role for endogenous natriuretic peptides in curbing
pathogenesis, and the therapeutic potential of this combina-
tion of NEPi PDEi in reversing the haemodynamic dysfunc-
tion and fibrotic processes that underpin lung fibrosis.
Materials and methods
Bleomycin-induced lung fibrosis
All animal care and experimental studies conformed to the
UK Animals (Scientific Procedures) Act 1986 and were
approved by the appropriate ethical committee of Queen
Mary University of London. All studies involving animals are
reported in accordance with the ARRIVE guidelines for
reporting experiments involving animals (Kilkenny et al.,
2010; McGrath et al., 2010). A total of 160 animals were used
in the experiments described here.
Mice were housed in a pathogen-free facility with access
to food and water ad libitum. Littermate wild-type (WT)
and natriuretic peptide receptor (NPR)-A knockout (KO)
mice (C57B6; male; 20–25 g; kind gift of O. Smithies, Univer-
sity of North Carolina) were exposed to bleomycin
(50 μL·mouse−1; 1 mg·kg−1 = ∼25 IU·per mouse) by oropharyn-
geal instillation under light isofluorane anaesthesia. Controls
were similarly instilled with 50 μL of sterile saline. Animals
were randomly assigned to the following groups:
• Control: saline-treated and receiving daily gavage with
vehicle for ecadotril (0.3 mL). This vehicle consists of 0.1%
polyethylene glycol + 0.5% carboxymethyl cellulose in
water.
• Bleomycin: bleomycin-treated and receiving daily gavage
with vehicle
• Bleomycin + sildenafil: bleomycin-treated and receiving
sildenafil (30 mg·kg−1 in drinking water) and daily gavage of
vehicle
• Bleomycin + ecadotril: bleomycin-treated and receiving
daily gavage of ecadotril (60 mg·kg−1 in vehicle)
• Bleomycin + sildenafil + ecadotril: bleomycin-treated and
receiving sildenafil (30 mg·kg−1 in drinking water) plus
daily gavage of ecadotril (60 mg·kg−1 in vehicle)
Treatment was started concomitantly with the adminis-
tration of bleomycin (i.e. day 0) and outcome measures
assessed at day 14. Doses of sildenafil and ecadotril were
BJP R S Baliga et al.
3464 British Journal of Pharmacology (2014) 171 3463–3475
chosen based on previous work (Stasch et al., 1995; Zhao
et al., 2001; Baliga et al., 2008).
In further experiments, to determine the ability of natriu-
retic peptides to reverse existing pulmonary fibrosis, mice
were exposed to bleomycin (as above), with treatment initi-
ated at day 14 and analysis undertaken at day 28. This ‘thera-
peutic dosing schedule’ was chosen after thorough, temporal
evaluation of the pathogenesis of the bleomycin model in our
laboratory (Scotton and Chambers, 2010), ensuring the pro-
gression of established fibrosis was targeted.
In vivo haemodynamic and
morphological analysis
Animals were anaesthetized using isofluorane (1.5%,
0.2 mL·min−1 oxygen), and right ventricular systolic pressure
(RVSP) and mean arterial blood pressure (MABP) were deter-
mined as described previously (Baliga et al., 2008). Following
haemodynamic measurements, animals were killed by exsan-
guination (under isofluorane anaesthesia, as above), hearts
excised, and right ventricle to left ventricle plus septum [RV/
(LV + S)] ratio determined as a measure of RVH.
Tissue processing and histochemistry
Inflated lungs were fixed in 4% paraformaldehyde for 4 h at
4°C and then incubated overnight in 15% sucrose in PBS at
4°C. Tissue was dehydrated in 70% ethanol and embedded in
paraffin. Serial sections (4 μm) were used for MSB (Martius/
Scarlet/Blue; DAKO, Ely, UK) staining and α-smooth muscle
actin (αSMA) immunohistochemistry. For the latter, sections
were incubated with a mouse monoclonal anti-αSMA anti-
body (DAKO; 1:1000 dilution), followed by biotinylated anti-
mouse secondary antibody. Immunoreactivity was detected
using the ABC-peroxide based system (DAKO) following the
manufacturer’s protocol. Stained slides were imaged by Nano-
zoomer virtual microscopy (Hamamatsu, Welwyn Garden
City, UK). Pulmonary arterial muscularization was then
assessed as previously described (Baliga et al., 2008). Briefly,
vessels were defined according to the presence or absence of
αSMA positive staining. Twenty five muscularized arteries
from different fields were imaged at 400 × magnification by
light microscopy from representative animals in each group
to determine wall thickness. All histology slides were coded
and evaluated without knowledge of the treatments.
Total lung collagen analysis
Collagen content was determined by measuring hydroxypro-
line by reverse-phase HPLC of 7-chloro-4-nitrobenzo-oxao-
1,3,-diazole-derived acid hydrolysates; the total lung collagen
was then calculated in mg, assuming lung collagen contains
12.2% (w/w) hydroxyproline (Scotton et al., 2009).
Human fibroblast differentiation
The ability of ANP (1 μM) and sildenafil (3 μM) alone, or in
combination, to prevent TGFβ-driven (1 ng·mL−1) human
lung fibroblast differentiation was evaluated as we have
described previously using primary human lung fibroblasts
isolated from macroscopically healthy segments of lung from
patients undergoing lung cancer resection (kind gift of Dr.
R.J. McAnulty, University College London) (Scotton et al.,
2009).
Quantitative real-time polymerase chain
reaction for pro-proliferative markers
The expression of mRNA for several pro-proliferative bio-
markers was conducted as we have described previously
(Scotton et al., 2009). Primers for inducible nitric oxide syn-
thase (iNOS), collagen (Col)-1a and β-actin were from Primer
Design (Southampton, UK); the others are shown in Table 1.
Biochemical analyses
Plasma ANP (Phoenix Pharmaceuticals, Karlsruhe, Germany)
and cGMP (GE Healthcare, Hatfield, UK) concentrations were
measured using commercially available ELISA.
Data analysis
Results are expressed as means ± SEM. Data were analysed by
one-way ANOVA with a Bonferroni post test where appropri-
ate. A Shapiro–Wilk test was applied to data sets to confirm
normal distribution. P < 0.05 denotes significance.
Materials
Bleomycin was supplied by Kyowa Hakko Kirin Co. Ltd,
Tokyo, Japan; ecadotril was a kind gift of Dr. Johannes-Peter
Stasch, Bayer AG, Wuppertal, Germany. TGFβ was from R&D
Systems, Oxford, UK; ANP was supplied by Cambridge Bio-
science, Cambridge, UK; isofluorane was from Abbott Labo-
ratories, Maidenhead, UK. Sildenafil was extracted from
tablets (Viagra, Pfizer, UK; dispensed by the UCLH pharmacy)
by crushing and dissolving in warm (40oC) water, filtration
and then acidification with HCl. Extraction was achieved
with ethyl acetate to give the free base. The citrate was regen-
erated from the free base by addition of one equivalent of
citric acid and warming in water followed by freeze drying.
The drinking water containing sildenafil was replaced with
fresh solution every 48 hours.
Results
Effect of sildenafil and ecadotril on
haemodynamic and cardiac parameters
Instillation of bleomycin markedly elevated RVSP compared
with saline-treated controls (32.0 ± 5.9 mmHg vs. 21.2 ±
Table 1
Primer sequences (5′→3′) used to quantify lung mRNA expression
GENE Primer sequence
αSMA Forward: AGAGTGGAGAAGCCCAGCCAGT
Reverse: CCAGAGCCATTGTCGCACACCA
TGFβ Forward: GGATACCAACTATTGCTTCAGCTCC
Reverse: AGGCTCCAAATATAGGGGCAGGGTC
IL-1β Forward: GACCTTCCAGGATGAGGACA
Reverse: CTAATGGGAACGTCACACACC
IL-13 Forward: CCTGGCTCTTGCTTGCCTT
Reverse: GGTCTTGTGTGATGTTTGCTCA
TNFα Forward: CAAATGGCCTCCCTCTCAT
Reverse: CACTTGGTGGTTTGCTACGA
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5.9 mmHg; P < 0.05). As monotherapy, neither sildenafil nor
ecadotril produced a significant reduction in RVSP in mice
receiving bleomycin (Figure 1A). However, the combination
of sildenafil plus ecadotril caused a significant fall in RVSP
when compared with bleomycin-treated mice. Indeed, the
effect of combination therapy was so substantial it virtually
reduced RVSP to control (saline-treated) levels (∼20 mmHg).
Neither sildenafil nor ecadotril, either alone or in combina-
tion, caused a significant change in MABP (Figure 1B).
Bleomycin-treated animals showed a significant increase
in RV/(LV + S) ratio, confirming the development of RVH in
this model. Treatment with sildenafil or ecadotril alone sig-
nificantly reduced the bleomycin-induced RVH. However,
combination treatment with sildenafil plus ecadotril caused
Figure 1
Right ventricular systolic pressure (RVSP) (A), mean arterial blood pressure (MABP) (B), right ventricle : left ventricle plus septum ratio [RV/(LV +
S)] (C), total heart weights (D), plasma (cGMP) (E), and plasma (ANP) (F) in saline-treated (control) mice and animals 14 days after exposure to
bleomycin (BLEO; 1 mg·kg−1) in the absence and presence of sildenafil (SILD; 30 mg·kg−1·day−1), ecadotril (ECAD; 60 mg·kg−1·day−1) or sildenafil
plus ecadotril (doses as above). #P < 0.05 versus saline control; *P < 0.05 versus bleomycin; $P < 0.05 versus bleomycin in the presence of sildenafil
or ecadotril monotherapy. n = 17–25 animals in each group for the haemodynamic measurements, n = 3–6 animals for the cGMP and ANP
concentrations.
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an additional reduction in RVH (Figure 1C). There were no
significant changes in total heart weight (Figure 1D).
Changes in pulmonary haemodynamics were mirrored by
the concentrations of cGMP and ANP in the plasma, which
were only significantly increased in the presence of combi-
nation therapy (Figure 1E and F).
Effect of sildenafil and ecadotril on
pulmonary vascular remodelling
Control animals showed only a modest degree of pulmonary
muscularization, which was significantly increased by bleo-
mycin (Figure 2A). Treatment with sildenafil, but not ecado-
tril (P = 0.07 vs. bleomycin), caused significant attenuation of
this bleomycin-induced muscularization. However, the com-
bination of sildenafil plus ecadotril produced a significantly
larger decrease in the percentage of muscularized arteries
compared with either treatment alone (Figure 2B). An essen-
tially identical pattern of activity was observed with respect
to vessel wall thickness (difference between the internal
and external diameter of αSMA-stained vessels (Figure 2C),
although in this instance ecadotril alone produced a signifi-
cant salutary effect on wall thickness.
Effect of sildenafil and ecadotril on
lung fibrosis
Bleomycin-injured animals exhibited typical fibrotic lesions
consisting of increased cellularity (including fibroblasts) and
deposition of extracellular matrix. Mice receiving combina-
tion treatment following bleomycin administration showed
a clear reduction in the incidence of fibrotic damage
(Figure 3A).
Bleomycin administration caused a significant increase in
total lung weight (Figure 3B), which was reduced in the pres-
ence of sildenafil, ecadotril or the combination (Figure 3B). In
Figure 2
Representative light microscopic images (scale bar = 200 μm) (A), and quantitative assessment of muscularization (B) and wall thickness (C) of
pulmonary arteries from saline controls, bleomycin (BLEO; 1 mg·kg−1)-treated animals, and mice receiving bleomycin in the presence of sildenafil
(SILD; 30 mg·kg−1·day−1), ecadotril (ECAD; 60 mg·kg−1·da−1) or sildenafil plus ecadotril (doses as above). Arrows indicate areas of overt muscu-
larization (αSMA staining). #P < 0.05 versus saline control; *P < 0.05 versus bleomycin; $P < 0.05 versus bleomycin in the presence of sildenafil or
ecadotril monotherapy. n = 17–25 animals in each group.
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accord, bleomycin induced a marked increase in the total
lung collagen content that was also attenuated by mono-
therapy or dual therapy (Figure 3C). In this case, the signifi-
cant salutary effects of sildenafil and ecadotril per se entailed
any supplementary advantage with combination treatment
was negligible. Nonetheless, the effect of each treatment on
collagen content was remarkable, with >80% attenuation in
each case.
Effect of sildenafil and ecadotril on the
expression of pro-fibrotic, pro-inflammatory
markers in the lung
To provide additional evidence that the combination therapy
exerted an anti-fibrotic effect in this model, we determined
the expression of mediators known to play a role in the
pathogenesis of IPF, including TGFβ, IL-1β, IL-13 and iNOS.
Figure 3
Representative light microscopic images of whole lung cross-sections (upper panels; scale bar = 4 mm) and higher magnification of the same
samples (lower panels; scale bar = 200 μm) stained with Martius/Scarlet/Blue (MSB) (A), and quantitative assessment of lung weight (B) and total
lung collagen (C) in saline controls, bleomycin (BLEO; 1 mg·kg−1)-treated animals, and mice receiving bleomycin in the absence and presence of
sildenafil (SILD; 30 mg·kg−1·day−1), ecadotril (ECAD; 60 mg·kg−1·day−1) or sildenafil plus ecadotril (doses as above). Arrows indicate areas of overt
fibrosis. #P < 0.05 versus saline control; *P < 0.05 versus bleomycin. n = 17–25 animals in each group.
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In addition, we assessed expression of mRNA for Col1a to
confirm the anti-fibrotic activity of combination therapy
observed in vivo affected collagen production at a transcrip-
tional level.
Bleomycin treatment resulted in a significant increase in
the expression of these mediators, which in accord with
effects on collagen deposition was significantly reduced by
combination treatment. Monotherapy did reduce the mRNA
expression for some mediators (e.g. ecadotril lowered the
expression of IL-13), but neither sildenafil nor ecadotril alone
was able to produce the wide-ranging inhibitory effect on
pro-fibrotic/pro-inflammatory pathways that dual therapy
delivered (Figure 4A–D and F). Intriguingly, the expression
of TNFα was enhanced by the combination treatment
(Figure 4E).
Effect of sildenafil and natriuretic peptides on
human fibroblast differentiation in vitro
One of the key steps in the development of pulmonary fibro-
sis is the differentiation of fibroblasts into αSMA-expressing
Figure 4
(A–F) Expression of mRNA encoding classical pro-fibrotic/pro-inflammatory mediators in the lungs of saline controls, bleomycin (BLEO; 1 mg·kg−1)-
treated animals, and mice receiving bleomycin in the presence of sildenafil (SILD; 30 mg·kg·−1day−1), ecadotril (ECAD; 60 mg·kg−1·day−1) or
sildenafil plus ecadotril (doses as above). #P < 0.05 versus saline control; *P < 0.05 versus bleomycin. n = 9 experiments for each group. (G)
Expression of α smooth muscle actin (αSMA) by human fibroblasts under control conditions or stimulated with TGFβ (1 ng·mL−1) in the absence
and presence of sildenafil (3 μM), atrial natriuretic peptide (ANP; 1 μM) or sildenafil plus ANP (at the same concentrations). #P < 0.05 versus saline
control; *P < 0.05 versus TGFβ; $P < 0.05 versus TGFβ in the presence of sildenafil or ecadotril monotherapy. n = 9 experiments for each group.
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myofibroblasts (driven principally by TGFβ) that secrete a
number of pro-proliferative factors, and are the major source
of collagen and extracellular matrix (Burgess et al., 2005;
Scotton and Chambers, 2007) that precipitate remodelling.
To demonstrate that combination therapy was effective in
inhibiting this pivotal step in the pathogenesis of fibrosis,
and to provide a rudimentary proof of concept in human
cells, we explored the ability of natriuretic peptides and
PDE5i to block human fibroblast differentiation in vitro.
TGFβ caused a rapid differentiation of human lung fibro-
blasts into myofibroblasts as quantified by the appearance of
αSMA positive cells (Figure 4G). In the presence of ANP or
sildenafil alone, there was a subtle decrease in the degree
of αSMA accumulation. However, the combination of ANP
pus sildenafil caused a synergistic inhibition of αSMA
up-regulation and fibroblast–myofibroblast differentiation
(Figure 4G).
Effect of NPR-A gene deletion on the
development of PH and fibrosis
In order to establish a role for endogenous natriuretic pep-
tides in limiting pathogenesis in IPF, and to confirm that
the beneficial effects of combination therapy are dependent
on natriuretic peptide bioactivity, we repeated representa-
tive studies in NPR-A KO animals. These mice lack the gua-
nylyl cyclase-linked receptor that acts as the principal target
for ANP and BNP (Potter et al., 2009). In these animals,
administration of bleomycin dramatically increased RVSP
beyond that observed in WT animals (Figure 5A), suggesting
that endogenous natriuretic peptides act in an intrinsic
defence capacity. While NPR-A KO animals exhibited a
higher MABP, this was not significantly altered by sildenafil,
ecadotril or the combination in WT or NPR-A KO mice
(Figure 5B). Bleomycin also aggravated RVH in NPR-A KO
animals, although this is masked somewhat by the inherent
left heart hypertrophy characteristic of this KO strain.
Importantly, the beneficial effects of the combination
therapy (sildenafil plus ecadotril) were diminished in NPR-A
KO mice (Figure 5C).
A similar profile of activity was observed with respect to
lung fibrosis. Bleomycin caused an increase in total lung
weight that was greater than that reached in WT animals
(Figure 5D). Nonetheless, the effect of combination treat-
ment to block the increase in lung weight was blunted in the
NPR-A KO mice (Figure 5D).
Effect of sildenafil and ecadotril on
established PH and lung disease
To more closely parallel the clinical situation, additional
investigations were conducted in which combination therapy
was initiated 2 weeks post-bleomycin, a so-called therapeutic
dosing regimen (Scotton and Chambers, 2010). In this case,
bleomycin caused the expected increase in RVSP, RVH, total
lung collagen and fibrosis (Figure 6A, B, D and E). Despite the
delayed administration of treatment, the combination of
sildenafil and ecadotril remained effective in reducing each of
these parameters (Figure 6A, B, D and E). As with prophylactic
treatment, neither sildenafil nor ecadotril, alone or in com-
bination, caused a change in MABP (Figure 6C).
Discussion
IPF is a progressive fibro-proliferative disorder with a poor
prognosis; this is largely the result of a complex and unde-
fined aetiology, and a lack of therapeutic options (Bjoraker
et al., 1998; Eickelberg and Selman, 2010). ILDs, including
IPF, are frequently complicated by the existence of PH; a dual
diagnosis that has a far less favourable outcome (Lettieri et al.,
2006; Mejia et al., 2009). We reported recently that augmen-
tation of natriuretic peptide bioactivity results in a significant
alleviation of disease severity in hypoxia-induced PH (Baliga
et al., 2008). This precedent, coupled with the well-defined
anti-fibrotic actions of natriuretic peptides in the heart and
kidney (Tamura et al., 2000; Soeki et al., 2005; Li et al., 2008;
Nishikimi et al., 2009; Das et al., 2010), provided the rationale
to explore the potential of manipulating natriuretic peptide
bioactivity in IPF. Data presented here suggest that this
approach may offer a substantial pharmacodynamic benefit
in IPF and associated PH as it combats both the haemody-
namic aberrations and fibro-proliferative aspects of the
disease.
Adopting a well-validated model of inflammation and
lung injury that is accepted as a model of human lung fibro-
sis (Scotton and Chambers, 2010), we demonstrate that
focusing efforts to maximize cGMP-dependent signalling,
using PDE5i and NEPi, offers a potent means of preventing
and reversing fibrosis and the accompanying PH. Adminis-
tration of bleomycin caused the expected increase in lung
fibrosis, significantly elevated RVSP and promoted RVH.
Neither of the components of the combination therapy (i.e.
sildenafil or ecadotril) significantly reduced RVSP at the doses
employed. However, this provided the ideal background to
reveal a clear synergy between the two drugs when admin-
istered together; this cooperative activity mirrored that
reported in models of hypoxia-induced PH and patients with
the disease (Zhao et al., 2003; Preston et al., 2004; Klinger
et al., 2006; Baliga et al., 2008). A salutary effect on the right
heart was also evident. Interestingly, the effects of the com-
bination therapy were greater (individually and in concert)
against structural changes in the right heart compared with
the haemodynamic dysfunction. This disparity suggests that
augmentation of natriuretic peptide function has direct
effects to slow or prevent cardiac hypertrophy, rather than
simply secondary to reducing pressure in the pulmonary cir-
culation. This is perhaps not surprising, since all three of the
principal members of the natriuretic peptide family exert
potent anti-hypertrophic effects in the heart (Tamura et al.,
2000; Knowles et al., 2001). This is a welcome finding since
the right heart is often neglected in the consideration of
novel therapies for IPF and PH, and treatment modalities
that directly preserve right heart structure and function are
likely to provide a valuable addition to the therapeutic rep-
ertoire. A further key facet of this PDE5i plus NEPi combina-
tion is that it appears to target the lung, as MABP was not
significantly affected. This selectivity is advantageous in IPF
and PH since it avoids the issue of systemic hypotension
while being able to maximize cGMP signalling in the pul-
monary circulation.
In response to increased resistance, the pulmonary circu-
lation remodels to accommodate the higher pressure and
maintain oxygenation. Induction of fibrosis with bleomycin
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also caused a dramatic increase in the number of muscular-
ized small pulmonary arteries. Akin to the positive effect
recorded in hypoxia-induced pH (Baliga et al., 2008), here the
remodelling of the pulmonary circulation was significantly
reduced by monotherapy with PDE5i or NEPi, with a clear
additive if not synergistic activity of dual therapy. This pro-
vides further evidence that augmenting natriuretic peptide
bioactivity exerts a multifaceted beneficial effect on many
haemodynamic aspects of pathogenesis in PH linked to IPF.
Undoubtedly, if these natriuretic peptide-driven salutary
actions translate to the clinical arena, combination treatment
should significantly improve outcome. Indeed, the beneficial
pharmacodynamic profile of PDE5i plus NEPi holds promise
in the treatment of many forms of PH as it appears that the
combination therapy is effective in models of PH with con-
trasting aetiologies.
Combination therapy also produced an impressive rever-
sal of the fibrotic aspects of lung disease. The outcome of
prophylactic treatment was manifested as a marked reduction
in the total lung weight, collagen deposition, and diminished
Figure 5
Right ventricular systolic pressure (RVSP) (A), mean arterial blood pressure (MABP) (B), right ventricle : left ventricle plus septum ratio [RV/(LV +
S)] (C), and total lung weight (D) in wild-type (WT) mice and natriuretic peptide receptor (NPR)-A KO animals exposed to saline, or bleomycin
(BLEO; 1 mg·kg−1) in the absence and presence of sildenafil (SILD; 30 mg·kg−1·day−1) plus ecadotril (ECAD; 60 mg·kg−1·day−1). #P < 0.05 versus
saline control; *P < 0.05 versus bleomycin; $P < 0.05 versus bleomycin-treated WT. n = 6–12 animals in each group.
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expression of a number of classically pro-inflammatory and
pro-fibrotic genes (e.g. TGFβ, IL-1β, IL-13) (Maher et al., 2007;
Scotton and Chambers, 2010; Farkas et al., 2011) in animals
exposed to bleomycin. A major criticism of the bleomycin
model is that prophylactic treatment regimens may dampen
the inflammatory phase of the response to bleomycin, with a
consequent reduction in fibrogenesis (rather than having
direct anti-fibrotic efficacy). To address this issue, we also
adopted a ‘therapeutic dosing strategy’, administering
therapy once fibrosis was already well established. Our data
again showed a remarkable effect of the combination therapy
on the increase in RVSP, RVH and total lung weight. Facilita-
tion of cGMP-dependent signalling by combination therapy,
therefore, exerts a key restraint on one of the central pro-
cesses leading to overt pulmonary fibrosis, that of extracellu-
lar matrix deposition.
Figure 6
Representative light microscopic images of (scale bar = 200 μm) (A), right ventricular systolic pressure (RVSP) (B), mean arterial blood pressure
(MABP) (C), right ventricle : left ventricle plus septum ratio [RV/(LV + S)] (D) and total lung weight (E) in saline controls, bleomycin (BLEO;
1 mg·kg−1)-treated animals, and mice receiving bleomycin in the presence of sildenafil (SILD; 30 mg·kg−1·day−1) plus ecadotril (ECAD;
60 mg·kg−1·day−1). Sildenafil and ecadotril were administered 2 weeks post-bleomycin exposure. #P < 0.05 versus saline control; *P < 0.05 versus
bleomycin. n = 6–10 animals in each group.
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To elucidate the mechanism of this anti-fibrotic action,
we investigated the effect of natriuretic peptides on fibroblast
differentiation (into highly synthetic and contractile αSMA-
expressing myofibroblasts), which underpins the synthesis
and deposition of extracellular matrix and is perceived to be
a key step in the development of IPF (Burgess et al., 2005;
Scotton and Chambers, 2007). In our experiments, ANP and
sildenafil showed no significant effect on fibroblast differen-
tiation individually, but in combination almost completely
prevented the differentiation. This fits well with the observa-
tions that circulating natriuretic peptide levels increase in
patients with pulmonary fibrosis (Burghuber et al., 1988;
Leuchte et al., 2004), advocating the belief that these tradi-
tionally cardioprotective mediators offer an innate defence
mechanism against (pulmonary) fibrosis. Indeed, there is
considerable precedent to support the thesis that natriuretic
peptides might exert a wide spectrum of activities that coun-
teract pulmonary fibrosis, thereby enhancing their creden-
tials as a novel therapeutic strategy. For example, natriuretic
peptides can prevent TGFβ-induced myofibroblast formation
from cardiac fibroblasts, probably by disrupting TGFβ-
induced nuclear translocation and downstream signalling of
pSmad3 (Kapoun et al., 2004). Moreover, in patients with
heart failure, TGFβ concentrations inversely correlate with
NT-proBNP levels (Behnes et al., 2011), and NPR-A KO mice
develop renal fibrosis that is associated with increased
epithelial–mesenchymal transition and expression of TGFβ
(Das et al., 2010). Indeed, blockade of Smad signalling
appears a common theme in the anti-TGFβ effects of natriu-
retic peptides since this phenomenon is observed in cardiac
fibroblasts, proximal tubular cells and pulmonary artery
smooth muscle cells (Kapoun et al., 2004; Li et al., 2008; Lo
et al., 2008); whether a similar intervention underlies the
beneficial effects of combination therapy in pulmonary fibro-
sis warrants further attention.
Inhibition of the expression and activity of principal pro-
inflammatory and pro-fibrotic cytokines critical in the devel-
opment of pulmonary fibrosis (Gasse et al., 2007; Scotton and
Chambers, 2007; 2010) appears another weapon in the anti-
fibrotic arsenal of natriuretic peptides. For example, TGFβ is
perhaps the best characterized and fundamental driver of
fibrotic lung disease; it promotes epithelial activation and
dysregulation, and facilitates fibroblast differentiation and
proliferation leading to collagen production and deposition
(Border and Noble, 1994; Willis and Borok, 2007). The Th2
cytokine IL-13 has been shown to promote fibrosis in a
number of experimental models (Wynn, 2003), and IL-13-
deficient mice exhibit exacerbated lung fibrosis (Kolodsick
et al., 2004). Inducible NOS also contributes to the develop-
ment of pulmonary fibrosis and underlies the response to a
number of pro-fibrotic cytokines, including IL-5 and IL-13
(Naura et al., 2010). iNOS expression is easily identifiable in
the lungs of patients with IPF (Saleh et al., 1997) and is
thought to expedite the development of fibrosis (Naura et al.,
2010). Each of these classically pro-fibrotic genes showed
enhanced expression following bleomycin treatment that
was significantly attenuated in mice treated with sildenafil
plus ecadotril. This widespread inhibition of the expression of
pro-fibrotic genes dovetails well with the favourable effects of
combination therapy on the haemodynamic and fibrotic
complications of bleomycin exposure, and suggest that phar-
macological augmentation of cGMP signalling has a multi-
pronged treatment effect. The mechanism(s) underpinning
this broad anti-fibrotic/anti-inflammatory influence of com-
bination therapy warrant further attention, but a similar
pattern of activity of natriuretic peptides has been reported in
acute lung injury (Koga et al., 2010); one plausible explana-
tion and common pathway is a cGMP-mediated inhibition of
NF-κB activity, perhaps via inhibition of phosphorylation
and degradation of the inhibitory subunit IκB, which has
been reported in vitro and in vivo (Moriyama et al., 2006;
Ladetzki-Baehs et al., 2007; Das et al., 2010). TNFα levels were
also increased in response to bleomycin, consistent with the
belief that this cytokine is involved in the pathogenesis of
fibrosis (Piguet et al., 1993; Zhang et al., 1993). Intriguingly,
we observed a slight enhancement of TNFα mRNA levels in
the bleomycin-treated mice that had received combination
therapy. As it was primarily considered a mitogen, anti-TNFα
therapies have been evaluated in a variety of fibrotic disor-
ders, but evidence suggests that these approaches may exac-
erbate disease severity, notably in pulmonary fibrosis
(Thavarajah et al., 2009). Our data suggest that TNFα has a
net anti-fibrotic effect, at least in the bleomycin experimental
model, perhaps due to a pro-apoptotic effect via the TNF
receptor-1 (Sun and Fink, 2007).
In the present study, by utilizing NPR-A KO mice, we
demonstrate that not only does augmentation of natriuretic
peptide signalling represent a tangible means to reduce
disease severity, but also that endogenous release of natriu-
retic peptide represents an intrinsic defence mechanism that
offsets the progression of pulmonary fibrosis. Using haemo-
dynamic (e.g. RVSP) and structural (e.g. RVH, total lung
weight) indices of pathogenesis, in animals lacking innate
natriuretic peptide bioactivity (i.e. NPR-A KO) pathology is
exacerbated. In addition, the beneficial effects of PDE5i plus
NEPi dual therapy were largely absent in NPR-A KO mice.
This finding confirms that the principal mechanism that
the dual therapy triggers to prevent or reverse pulmonary
fibrosis is augmentation of the bioactivity of ANP and/or
BNP. This is a key point since NEP metabolizes a number
of vasoactive peptides, such as endothelin-1, bradykinin,
and vasoactive intestinal peptide (Campbell, 2003), yet it
appears that it is primarily the enhancement of the cyto-
protective effects of natriuretic peptides that underpins the
efficacy of combination treatment in IPF. This conclusion is
supported by the observation that plasma ANP and cGMP
levels were only significantly increased by combination
therapy.
In summary, a combination therapeutic strategy targeted
to enhance natriuretic peptide activity (NEPi) and prevent
cGMP catabolism (PDE5i) is a potent and effective combina-
tion that prevents and reverses the fibrosis and accompany-
ing PH in bleomycin-induced lung inflammation and injury.
Moreover, natriuretic peptides represent an intrinsic cytopro-
tective pathway that is triggered during the pathogenesis of
pulmonary fibrosis and that offsets disease progression.
Therefore, this NEPi/PDE5i drug combination might be a
novel therapeutic approach in IPF, which currently has little
or no disease-modifying therapy, and consequently signifi-
cant associated morbidity andmortality. As both components
of the combination are licensed drugs, efficacy in IPF patients
can be evaluated rapidly and inexpensively. This approach,
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therefore, shows promise to improve outcome and lower
healthcare costs in this patient cohort.
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